Arena Pharma (ARNA) Shares Now Up ~130% Since Positive FDA Panel Vote on Lorcaserin
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) shares are continuing higher Wednesday as investors continue to anticipate a good outcome from its scheduled PDUFA on June 27th for its proposed weight-loss drug lorcaserin.
Shares are up 136 percent following a positive FDA advisory panel vote made on May 10th.
The Stock is up an additional 8.8 percent Wednesday.
Shares are up 136 percent following a positive FDA advisory panel vote made on May 10th.
The Stock is up an additional 8.8 percent Wednesday.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
